Page 4«..3456..1020..»

Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

Posted: November 12, 2024 at 2:47 am

Revenues increased 17% compared to the previous quarter ended June 30, 2024

Original post:
Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

Posted in Global News Feed | Comments Off on Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Posted: November 12, 2024 at 2:47 am

SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 3:30 p.m. GMT, in London, UK.

Go here to see the original:
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Posted in Global News Feed | Comments Off on Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

Posted: November 12, 2024 at 2:47 am

—Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset—

More:
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

Posted in Global News Feed | Comments Off on Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Posted: November 12, 2024 at 2:47 am

CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA).

Read more from the original source:
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Posted in Global News Feed | Comments Off on Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future

Posted: November 12, 2024 at 2:47 am

Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million

Read more from the original source:
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future

Posted in Global News Feed | Comments Off on 23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

Posted: November 12, 2024 at 2:47 am

LA JOLLA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it was notified by Sanofi that the Sanofi/Novartis litigation was settled. Accordingly, MediciNova is entitled to receive a certain amount of monetary damages through this settlement. Further details will be provided as they become available.

Read the rest here:
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

Posted in Global News Feed | Comments Off on MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

Santhera Enters into Exclusive Supply Agreement for AGAMREE® (Vamorolone) with Ali Al Suwaidi Trading Establishment (ASTE) in Qatar

Posted: November 12, 2024 at 2:47 am

Pratteln, Switzerland, November 12, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive supply agreement with Ali Al Suwaidi Trading Est. (ASTE) for the treatment of patients with Duchenne muscular dystrophy (DMD) with AGAMREE under a Named Patient Program.

Link:
Santhera Enters into Exclusive Supply Agreement for AGAMREE® (Vamorolone) with Ali Al Suwaidi Trading Establishment (ASTE) in Qatar

Posted in Global News Feed | Comments Off on Santhera Enters into Exclusive Supply Agreement for AGAMREE® (Vamorolone) with Ali Al Suwaidi Trading Establishment (ASTE) in Qatar

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Posted: November 12, 2024 at 2:47 am

Saint-Herblain (France), November 12, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe.

Continue reading here:
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Posted in Global News Feed | Comments Off on Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Posted: November 12, 2024 at 2:47 am

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the third quarter ended September 30, 2024, and provided a general business update.

Read this article:
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Posted in Global News Feed | Comments Off on Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

Posted: November 12, 2024 at 2:47 am

PARIS and CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and reported financial results for the third quarter of 2024.

Follow this link:
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

Posted in Global News Feed | Comments Off on NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

Page 4«..3456..1020..»